Topical henna for capecitabine induced hand-foot syndrome

被引：36

作者：

Yucel, Idris ^{[1
]}

Guzin, Gonullu ^{[1
]}

机构：

[1] Ondokuz Mayis Univ, Sch Med, Dept Med Oncol, TR-55139 Kurupelit, Turkey

来源：

INVESTIGATIONAL NEW DRUGS | 2008年 / 26卷 / 02期

关键词：

henna; capecitabine; hand-foot;

D O I：

10.1007/s10637-007-9082-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Capecitabine is a chemotherapeutic drug for use in cancers. Hand-foot syndrome (HFS) is side effect of capecitabine which can lead the cessation of the therapy or dose reduction. Henna (Lawsonia inermis) is a traditionally used plant of Middle-East that is applied on hands and feet. Some of cancer patients in capecitabine treatment who developed HFS, we recommended to apply henna. In these patients, six patients were grade 3 HFS and four were grade 2 HFS. Complete response (CR) were seen in four of grade 3 HFS and all of grade 2; two grade 3 HFS improved to grade 1. So far, in the chemotherapy, there was no need of dose reduction and also no side effect of henna seen. Clinical improvement in these patients may relate to anti-inflammatory, antipyretic and analgesic effects of henna. Prospective studies are needed to show this therapeutic effect of henna.

引用

页码：189 / 192

页数：4

共 50 条

[41] Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies
Rodriguez-Garzotto, Analia
Iglesias-Docampo, Lara
Vanesa Diaz-Garcia, C.
Ruppen, Isabel
Ximenez-Embun, Pilar
Gomez, Carlos
Luis Rodriguez-Peralto, J.
Ortiz de Frutos, Javier
Lopez-Martin, Jose A.
Gravalos, Cristina
Cortes-Funes, Hernan
Teresa Agullo-Ortuno, M.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[42] Hand and foot syndrome secondary to capecitabine
Lai, Hina Shaikh
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2014, 80 (05) : 427 - 430
[43] Case series of docetaxel-induced dorsal hand-foot syndrome
Patel, Jolly
Ringley, J. Tanner
Moore, Donald C.
THERAPEUTIC ADVANCES IN DRUG SAFETY, 2018, 9 (08) : 495 - 498
[44] A novel animal model of tegafur-induced hand-foot syndrome
Takano-Mochizuki, Misato
Nakajima, Kota
Ishida, Tomomi
Ohta, Etsuko
Moriyama, Tomoyuki
Asakura, Shoji
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2024, 487
[45] Thymidine phosphorylase as a molecular target for quercetin-incorporated collagen matrix in the prevention of hand-foot syndrome induced by capecitabine in rats
Mashaly, Maryam E.
Kotb, Hams M.
Abdin, Amany A.
Hedya, Sabiha E.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2023, 101 (07) : 340 - 348
[46] Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials
Kao, Yung-Shuo
Lo, Chen-Hsu
Tu, Yu-Kang
Hung, Cheng-Hsien
DERMATOLOGIC THERAPY, 2022, 35 (10)
[47] CapecitabineHyperpigmentation and hand-foot syndrome: case report
Reactions Weekly, 2012, 1404 (1) : 12 - 12
[48] Compliance and Effective Manapement of the Hand-Foot Syndrome in Colon Cancer Patients Receiving Capecitabine as Adjuvant Chemotherapy
Son, Hyun-Sook
Lee, Woo Yong
Lee, Won-Suk
Yun, Seong Hyeon
Chun, Ho-Kyung
YONSEI MEDICAL JOURNAL, 2009, 50 (06) : 796 - 802
[49] A cross-sectional survey of methods for controling hand-foot syndrome in patients receiving capecitabine treatment
Suzuki, Shinya
Nawata, Shuichi
Inada, Yusuke
Sato, Daisuke
Kusano, Junichi
Ichikura, Daisuke
Torigoe, Kazuhiro
Ishitsuka, Kazumi
Sato, Fumiaki
Sakai, Hiroyasu
Yumoto, Tetsuro
MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (04) : 443 - 448
[50] Hand-Foot Syndrome Accompanied by Severe Oral Lesions during Capecitabine Therapy for Metastatic Colon Carcinoma
Serdar, Zehra Asiran
Gonenc, Isik
Yasar, Sirin
Doruk, Tugba
Doner, Nurhan
MARMARA MEDICAL JOURNAL, 2011, 24 (03): : 200 - 202

← 1 2 3 4 5 →